Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Inventory (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Change in Inventory for 14 consecutive years, with -$3.7 million as the latest value for Q4 2025.

  • Quarterly Change in Inventory fell 652.89% to -$3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, down 72.0% year-over-year, with the annual reading at $6.0 million for FY2025, 72.0% down from the prior year.
  • Change in Inventory hit -$3.7 million in Q4 2025 for Ani Pharmaceuticals, down from $8.2 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $11.6 million in Q2 2024 to a low of -$5.9 million in Q3 2021.
  • Historically, Change in Inventory has averaged $2.7 million across 5 years, with a median of $1.9 million in 2022.
  • Biggest five-year swings in Change in Inventory: skyrocketed 1635.58% in 2024 and later tumbled 652.89% in 2025.
  • Year by year, Change in Inventory stood at $5.5 million in 2021, then surged by 70.52% to $9.5 million in 2022, then crashed by 51.33% to $4.6 million in 2023, then tumbled by 85.34% to $675000.0 in 2024, then crashed by 652.89% to -$3.7 million in 2025.
  • Business Quant data shows Change in Inventory for ANIP at -$3.7 million in Q4 2025, $8.2 million in Q3 2025, and $908000.0 in Q2 2025.